4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-013289
Chief Financial Officer sold 32,500 shares at an average $26.94 ($875,451)
- Chief Financial Officer acquired 32,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| FRATES JAMES M Chief Financial Officer | 2023-05-16 | Option exercise 10b5-1 | +32,500 | $6.88 | $223,600 | 88,176 | D |
| FRATES JAMES M Chief Financial Officer | 2023-05-16 | Sale 10b5-1 | −32,000 | $26.93 | $861,651 | 56,176 | D |
| FRATES JAMES M Chief Financial Officer | 2023-05-16 | Sale 10b5-1 | −500 | $27.60 | $13,800 | 55,676 | D |
| Derivatives | |||||||
| FRATES JAMES M Chief Financial Officer | 2023-05-16 | Option exercise · Stock Option (right to buy) 10b5-1 | −32,500 | 382,000 | D | ||
| Open-market sales · 32,500 sh · avg $26.94 · $875,451 | |||||||
Loading xslF345X04/doc4.xml…